The overall hypothesis is that the cellular responses to amyloid beta (A beta ) that culminate in the cell dysfunction and degeneration characteristic of Alzheimer disease (AD) are dependent on the specific structure of the supramolecular aggregates formed by the A beta peptides. The applicants propose that part of the process of maturation of the predominantly diffuse, non-neuritic amyloid plaques of """"""""normal"""""""" aging into the neuritic plaques associated with dementia involves the generation of these specific A beta structures. Extending this hypothesis, the applicants further propose that the generation of """"""""toxic"""""""" supramolecular structures of A beta aggregates can be influenced by the presence of other plaque components, particularly those components derived from glia, and that responses of glial cells contribute to an environment that facilitates and enhances the formation of these bioactive A beta forms. It is their contention that glia are not just passive bystanders, but are a part of the pathogenesis process. They postulate that A beta toxicity can be mediated through its effects on glia, that glia-derived proteins can influence the structure of A beta and its effects on neurons, and that these processes are relevant to the actual neuropathology seen in the AD brain. The questions being addressed in these studies are: What does A beta do to glia? What do glia do to A beta structure and activity? Are glia relevant to AD neuropathology? Three aims are proposed to address these questions. 1) They will evaluate the effects of A beta on glia. Specific A beta aggregates will be prepared, characterized by atomic force microscopy (AFM), and tested for activity on cultures of rat primary astrocytes. The investigators will examine the effects of A beta on the levels and activity of six relevant glial proteins: a 1-antichymotrypsin (ACT), apolipoprotein E (apoE), apoJ, butyrylcholinesterase (BChE), interleukin-1 (IL-1), and S100 beta . 2) They will evaluate the effects of glia on A beta structure and neurotoxicity. In co-aggregation experiments, they will evaluate AFM structure of A beta aggregates formed in the presence of the six glial proteins studied in aim 1. The investigators will also test A beta -evoked neurotoxicity in the presence of these six glial proteins and in glial-neuronal co-cultures. 3) They will correlate the presence and distribution of glial proteins with plaque type in AD brain. They will determine the regional distribution and immunoreactive density of the six glial proteins in AD and control brain tissue, and establish correlations with the distribution of non-neuritic vs neuritic plaques. This system examination should provide insight into how A beta affects glia, and how glia participate in amyloid plaque progression and development of neurotoxicity.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project (R01)
Project #
5R01AG013939-03
Application #
2732608
Study Section
Neurological Sciences Subcommittee 1 (NLS)
Project Start
1996-09-19
Project End
2000-06-30
Budget Start
1998-07-01
Budget End
1999-06-30
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Barone, Eugenio; Di Domenico, Fabio; Sultana, Rukhsana et al. (2012) Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med 52:2292-301
Sultana, Rukhsana; Robinson, Renã A S; Di Domenico, Fabio et al. (2011) Proteomic identification of specifically carbonylated brain proteins in APP(NLh)/APP(NLh) × PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice model of Alzheimer disease as a function of age. J Proteomics 74:2430-40
Chico, Laura K; Van Eldik, Linda J; Watterson, D Martin (2009) Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov 8:892-909
Lloyd, Eric; Somera-Molina, Kathleen; Van Eldik, Linda J et al. (2008) Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J Neuroinflammation 5:28
Borders, Aaron S; de Almeida, Lucia; Van Eldik, Linda J et al. (2008) The p38alpha mitogen-activated protein kinase as a central nervous system drug discovery target. BMC Neurosci 9 Suppl 2:S12
Wing, Laura K; Behanna, Heather A; Van Eldik, Linda J et al. (2006) De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders. Curr Alzheimer Res 3:205-14
Ralay Ranaivo, Hantamalala; Craft, Jeffrey M; Hu, Wenhui et al. (2006) Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration. J Neurosci 26:662-70
Guo, Ling; LaDu, Mary Jo; Van Eldik, Linda J (2004) A dual role for apolipoprotein e in neuroinflammation: anti- and pro-inflammatory activity. J Mol Neurosci 23:205-12
Craft, Jeffrey M; Van Eldik, Linda J; Zasadzki, Magdalena et al. (2004) Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation. J Mol Neurosci 24:115-22
Craft, Jeffrey M; Watterson, D Martin; Frautschy, Sally A et al. (2004) Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo. Neurobiol Aging 25:1283-92

Showing the most recent 10 out of 40 publications